21st Mar 2005 10:51
Prelude Trust PLC21 March 2005 For immediate release: 21 March 2005 PRELUDE EXITS FROM OXFORD BIOMEDICA PLC Prelude Trust plc ("Prelude"), the investment trust that specialises in earlystage, technology-based businesses, announces that it has completed the sale ofits remaining shareholding in Oxford Biomedica PLC ("Oxford Biomedica"). Preludeinvested a total of £2.2 million in Oxford Biomedica during 1998 and 2001 andhas now realised a total of £5.0 million through the sale of its shareholdingbetween 2003 and 2005. Oxford BioMedica is a biopharmaceutical company specialising in the developmentof novel gene-based therapeutics with a focus on the areas of oncology andneurotherapy. The Company was established in 1995 as a spin out from OxfordUniversity. Commenting on the investment, Robert James, a Director of Prelude Ventures,said, "We were delighted to have been investors in Oxford Biomedica and to havemore than doubled our initial investment. We wish them all the very best in thefuture development of their business." Prelude will be announcing its quarterly unaudited NAV figure for the threemonths to 31 March 2005 in early April. For further information, please visit www.prelude-ventures.com or contact: Robert James/Jayne Tamblin John West/Clemmie Carr Prelude Trust plc Tavistock CommunicationsTel: 01954 288 090 Tel: 020 7920 [email protected] [email protected] This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Oxford Biomedica